Research programme: sigma receptor-targeting therapeutics - Esteve
Alternative Names: Sigma therapeutics - EsteveLatest Information Update: 16 Jul 2016
At a glance
- Originator Esteve
- Developer ESTEVE
- Class
- Mechanism of Action Sigma receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain; Psychotic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Spain
- 16 Jan 2015 9173588 - triggered, not included, did not addd collab into this profile (looks like it concerns only clinical compounds; rendered ref to E 52862 as per guidelines
- 02 Jun 2005 Preclinical trials in Pain in Spain (unspecified route)